# Sitagliptin Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus

> **NCT00337610** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 190 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus (T2DM)

## Interventions

- **DRUG:** sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day
- **DRUG:** comparator: placebo to match sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day

## Key facts

- **NCT ID:** NCT00337610
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2007-05
- **Final completion:** 2007-08
- **Target enrollment:** 190 (ACTUAL)
- **Last updated:** 2016-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00337610

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00337610, "Sitagliptin Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus". Retrieved via MORVS 2026-10-10 from https://api.morvs.ai/clinical/NCT00337610. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*